Sponsors Flesh Out Profiles of New Dermatology Drugs At AAD Meeting
Executive Summary
Additional data for J&J's guselkumab, Regeneron/Sanofi's Dupixent, Lilly's Taltz and UCB/Dermira's Cimzia featured at the American Academy of Dermatology meeting in Orlando, Fla. March 3-7.
You may also be interested in...
AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount
Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.
Keeping Track: Review Underway For Linhaliq, New Uses Of Lenvima, Cimzia; New Cycle Starts For Lutathera
The latest drug development news and highlights from our US FDA Performance Tracker.
Pressed Sanofi CEO Hopes For Positive Dupixent Launch, Praluent Ruling
Sanofi's CEO Olivier Brandicourt's reassuring 2017 guidance relies on continued cost savings, a successful launch of its Dupixent biologic, and winning a US legal case that threatens its PCSK9 inhibitor Praluent.